First Wilshire Securities Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

First Wilshire Securities Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-73,333	Closed	-$83K	–	87
2022 Q2	$83K	Hold	73,333	–	–	0.03%	84
2022 Q1	$374K	Hold	73,333	–	–	0.13%	61
2021 Q4	$413K	Hold	73,333	–	–	0.13%	57
2021 Q3	$812K	Hold	73,333	–	–	0.27%	34
2021 Q2	$1.24M	Buy	73,333 +63,333	+633%	+$1.2M	0.44%	29
2021 Q1	$263K	Buy	+10,000	New	+$455K	0.1%	72

Other funds holding EVFM

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

First Wilshire Securities Management's EVFM Position: Q3 2022 in Review

First Wilshire Securities Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 73,333 shares — an estimated $83K sold.

First Wilshire Securities Management first reported a position in EVFM in Q1 2021 and held it in 6 quarters. The position peaked at $1.24M in Q2 2021. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

First Wilshire Securities Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
First Wilshire Securities Management sold 73,333 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $83K.
First Wilshire Securities Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
First Wilshire Securities Management's Evofem Biosciences, Inc. Common Stock position peaked at $1.24M in Q2 2021.
8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on First Wilshire Securities Management's 13F filing for Q3 2022, filed 14 Nov 2022.